Introduction
============

Rheumatoid arthritis (RA) is a chronic autoinflammatory disorder of joints, which is characterized by irreversible joint damage and destruction of cartilage and bone, leading to severe disability or even premature death ([@ref-1]). It affects approximately 1% of the population worldwide, and reduces life expectancy of patients by 3--18 years. There are 25--50 new cases in a population of 100,000 worldwide each year ([@ref-11]; [@ref-27]; [@ref-23]).

The etiology and pathophysiology of RA are not well understood ([@ref-22]). It is widely acknowledged that RA is triggered by the complex interaction among genetic susceptibility, autoimmune disorders and dysregulated genes.

For genetic susceptibility, several studies have demonstrated that expression quantitative trait loci (eQTL) single nucleotide polymorphisms (SNPs) increase the risk of RA. A recent study indicates that *HLA-DOA* rs369150-A polymorphism reduces the expression of *HLA-DOA*, which independently associates with RA risk in the Japanese population, Asian population (Chinese and Korean) and European population ([@ref-24]). eQTL of GZMB identifies higher expression in the presence of the minor allele of [rs8192916](http://www.ncbi.nlm.nih.gov/snp/?term=rs8192916), which is associated with progression of joint destruction in RA ([@ref-17]). For dysregulated genes, down-regulation of miR-126 inhibits PI3K/AKT signaling pathway and disrupts the imbalance between cell growth and cell death of rheumatoid arthritis synovial fibro-blasts by targeting PIK3R2 ([@ref-10]). Over-expression of TLR-2 and IL-6 decrease the expression of FCRL4, might contribute to the RA process ([@ref-16]; [@ref-9]).

Previous studies demonstrate that early diagnosis and treatment will be beneficial to reduction of progressive joint injury of patients with RA. Currently, several biomarkers such as citrullinated proteins, rheumatoid factor, S100 proteins, matrix metalloproteinases and serum amyloid proteins have been described ([@ref-33]), but these biomarkers have limitations on sensitivity and or specificity in routine clinical practice. The early diagnosis of RA remains challenging.

In this study, we used bioinformatics methods to integrate mRNA expression datasets, which were available in the Gene Expression Omnibus database, identified DEGs in synovial tissues of patients with RA and healthy individuals, aiming to investigate the potential pathogenesis mechanism of RA and provide valuable information for the identification of potential diagnosis biomarkers in RA.

Materials and Methods
=====================

Data collection
---------------

NCBI Gene Expression Omnibus (GEO) database provides a large collection of microarray expression data ([@ref-8]). "Rheumatoid Arthritis" was used as the key word to search expression profiling of RA. The inclusion criteria of datasets were set as follows: (1) whole genome expression data of RA; (2) the expression profiling of synovial tissues was generated from patients with RA and healthy individuals.

Total of nine mRNA expression datasets of synovial tissues of RA were incorporated into our study. Four datasets were based on GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array, four datasets were based on GPL96 \[HG-U133A\] Affymetrix Human Genome U133A Array, and one dataset was based on GPL91 \[HG_U95A\] Affymetrix Human Genome U95A Array.

Data preprocessing and Identification of DEGs
---------------------------------------------

The raw expression datasets were downloaded and preprocessed by log2 transformation in R language ([@ref-32]). The Linear Models "limma" package in R language was used to analyze the microarray datasets ([@ref-34]). Differentially expressed genes were identified in patients with RA compared to healthy individuals. The false discovery rate (FDR) ([@ref-29]) was utilized for multiple testing corrections by using the Benjamini and Hochberg method. FDR \< 0.05 was set as the threshold of DEGs.

Heatmap analysis
----------------

To assess the similarity of gene expression patterns between two samples, two-way hierarchical clustering analysis ([@ref-3]) was performed. The heatmap was constructed using 'pheatmap' package in R language.

Functional annotation of DEGs
-----------------------------

The significantly dysregulated genes between patients with RA and healthy individuals were filtered as DEGs. In order to understand the biological roles of DEGs, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) terms were enriched by the online tool GeneCoDis3 ([@ref-14]; [@ref-4]; [@ref-36]). The threshold of GO function and KEGG pathway enrichment were FDR \< 0.05.

Protein--protein interaction network
------------------------------------

In order to explore the interaction between the top 10 up- and down-regulated DEGs in synovial tissues of patients with RA, BioGRID, a database of known protein interactions, was used to predict the PPI association among DEGs and the PPI interaction network was visualized by Cytoscape ([@ref-31]; [@ref-7]).

Construction of transcription factors regulatory network
--------------------------------------------------------

TRANSFAC ([@ref-43]) is a database covering details of TFs and their DNA binding sites. In our analysis, the TFs in the human genome and the motifs of genomic binding sites were downloaded from the TRANSFAC. Moreover, the 2 KB sequence in the upstream promoter region of top 10 up- and down-regulated DEGs was downloaded from UCSC (<http://www.genome.ucsc.edu/cgi-bin/hgTables>). Target sites of potential TFs were then distinguished. The TFs and its target genes were used for constructing regulatory network, and the network was visualized by Cytoscape software (<http://cytoscape.org/>) ([@ref-31]). Nodes represented TFs or target genes and lines represented association between TFs and target genes.

The DEGs were analyzed in the [GSE17755](GSE17755) datasets
-----------------------------------------------------------

We obtained a number of key DEGs in RA synovial tissues based on the bioinformatics analyses. In order to analyze whether those DEGs were dysregulated in peripheral blood cells of patients with RA, the expression levels of representative DEGs were preliminarily validated in the expression profiling of peripheral blood cells of patients with RA from the publicly available GEO dataset. "Rheumatoid arthritis" was used as the key word to search the expression profiling in the GEO database. The mRNA expression profiling datasets were included based on the following criteria: (1) the dataset was generated from the peripheral blood cells of patients with RA; (2) The expression profiling of peripheral blood cells of RA patients and healthy individuals were available in the dataset; (3) the RA patients had no treatment record before peripheral blood cells collection. Finally, [GSE17755](GSE17755) and [GSE15573](GSE15573) were left. A total of 18 patients with RA and 15 healthy individuals were included in the [GSE15573](GSE15573) datasets, which had the smaller sample size compared to [GSE17755](GSE17755). There were 112 patients with RA and 45 healthy individuals in [GSE17755](GSE17755) dataset. Based on aforementioned information, [GSE17755](GSE17755) was incorporated into ours study ([@ref-18]). Box-plot analysis was performed to preliminarily detect the expression levels of DEGs in peripheral blood cells of RA patients and health individuals.

Quantitative real-time polymerase chain reaction (qRT-PCR)
----------------------------------------------------------

In order to validate the expression levels of candidate genes in RA, 10 peripheral blood samples were collected from RA patients, who were diagnosed at the Affiliated Zhongshan Hospital. Moreover, 10 matched peripheral blood samples were collected from healthy individuals. This work was approved by the Ethics Committee of the Affiliated Zhonghan Hospital and informed written consent was obtained from all patients. The research complied with the principles of the Declaration of Helsinki.

Total RNA of peripheral blood samples were extracted by using Trizol (Invitrogen, Carlbad, CA, USA) according to the manufacture instructions. FastQuant cDNA Synthesis Kit (Tiangen, Beijing, China) was used to synthesize the cDNA of mRNA. qRT-PCR reactions were performed by using SuperReal PreMix Plus SYBR Green Kit (Tiangen, Beijing, China) on Applied Biosystems 7500 (Applied Biosystems, Foster City, CA, USA). GAPDH were used as internal control for mRNA detection. The PCR primers used in our study were shown as follows: GAPDH forward primer 5′ GGA GCG AGA TCC CTC CAA AAT 3′, reverse primer 5′ GGC TGT TGT CAT ACT TCT CAT GG 3′; MAT2A forward primer 5′ ATG AAC GGA CAG CTC AAC GG 3′, reverse primer 5′ CCA GCA AGA AGG ATC ATT CCA G 3′; NSA2 forward primer 5′ CAC CGT AAA CGC TAT GGA TAC C 3′, reverse primer 5′ GCT TAG CCT TCA GAC CAA TCA TT 3′; CD47 forward primer 5′ TCC GGT GGT ATG GAT GAG AAA 3′, reverse primer 5′ ACC AAG GCC AGT AGC ATT CTT 3′. At least triple experiments were subjected to qRT-PCR verification. The relative expression of candidate genes was calculated by using the ΔCT equation methods. Mean ± standard deviation and independent-samples *t*-test was used in the statistical analysis. *P* \< 0.05 was considered as significant difference. \* indicated *P* \< 0.05; \*\* indicated *P* \< 0.01.

Results
=======

Differentially expressed genes in RA
------------------------------------

Nine mRNA expression profiles of RA synovial tissues, including 168 patients with RA and 41 healthy individuals, were incorporated into our study ([Table 1](#table-1){ref-type="table"}). In our analysis, a total of 378 DEGs including 202 up- and 176 down-regulated genes were identified in patients with RA compared to healthy individuals. LCK and MAT2A were the most significantly up- and down-regulated genes in RA, respectively ([Table 2](#table-2){ref-type="table"}). The expression pattern of the top 200 DEGs in RA patients and healthy individuals was shown in [Fig. 1](#fig-1){ref-type="fig"}, which indicated that the mRNA expression profiling of synovial tissues of RA patients was different from healthy individuals.

10.7717/peerj.3078/table-1

###### The expression profiling of patients with RA and normal controls.

![](peerj-05-3078-g006)

  GEO ID                 Sample (N:P)   Platform                                                               Year   Author                    Country
  ---------------------- -------------- ---------------------------------------------------------------------- ------ ------------------------- -------------
  [GSE77298](GSE77298)   7:16           GPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array   2016   Mathijs G.A. Broeren      Netherlands
  [GSE48780](GSE48780)   0: 83          GPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array   2014   Sarah K. Kummerfeld       USA
  [GSE55235](GSE55235)   10:10          GPL96\[HG-U133A\] Affymetrix Human Genome U133A Array                  2014   Thomas Häupl              Germany
  [GSE55457](GSE55457)   10:13          GPL96\[HG-U133A\] Affymetrix Human Genome U133A Array                  2014   Raimund W. Kinne          Germany
  [GSE55584](GSE55584)   0:10           GPL96\[HG-U133A\] Affymetrix Human Genome U133A Array                  2014   Woetzel D                 Germany
  [GSE36700](GSE36700)   0:7            GPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array   2012   Bernard Robert Lauwerys   Belgium
  [GSE24742](GSE24742)   0:12           GPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array   2010   Bernard Robert Lauwerys   Belgium
  [GSE12021](GSE12021)   9:12           GPL96\[HG-U133A\] Affymetrix Human Genome U133A Array                  2008   René Huber                Germany
  [GSE1919](GSE1919)     5:5            GPL91\[HG_U95A\] Affymetrix Human Genome U95A Array                    2004   Ungethuem U               Germany

**Notes.**
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###### The top 10 up- and down-regulated DEGs in RA.

![](peerj-05-3078-g007)

  Gene ID                          Gene Symbol   *p*-Value      FDR            Regulation
  -------------------------------- ------------- -------------- -------------- ------------
  **Top 10 up-regulated DEGs**                                                 
  3932                             LCK           0              0              Up
  6964                             TRD           1.65645E--13   4.7104E--10    Up
  26135                            SERBP1        1.95311E--10   3.33239E--07   Up
  8711                             TNK1          2.47189E--09   3.01253E--06   Up
  7456                             WIPF1         3.19709E--08   2.72744E--05   Up
  5209                             PFKFB3        3.67501E--08   2.85014E--05   Up
  23543                            RBFOX2        6.50956E--08   3.7022E--05    Up
  56681                            SAR1A         7.13709E--08   3.80541E--05   Up
  961                              CD47          8.72732E--08   4.13626E--05   Up
  9669                             EIF5B         9.36124E--08   4.20319E--05   Up
  **Top 10 down-regulated DEGs**                                               
  4144                             MAT2A         1.27898E--13   4.7104E--10    Down
  1388                             ATF6B         9.32052E--11   1.98783E--07   Down
  26148                            C10orf12      6.51139E--10   9.25812E--07   Down
  6949                             TCOF1         5.24047E--09   5.58831E--06   Down
  2516                             NR5A1         8.37334E--09   7.937E--06     Down
  6897                             TARS          4.75819E--08   3.12247E--05   Down
  5463                             POU6F1        4.41294E--08   3.12247E--05   Down
  10412                            NSA2          5.26449E--08   3.20795E--05   Down
  763                              CA5A          8.50556E--08   4.13626E--05   Down
  23387                            SIK3          1.4221E--07    5.77712E--05   Down

**Notes.**
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GO classification of DEGs in RA
-------------------------------

DEGs in patients with RA were performed to GO annotation for investigating the biological roles. The threshold of the GO terms was set as FDR \< 0.001. As [Table 3](#table-3){ref-type="table"} shown, RNA splicing (GO: 0007585), signal transduction (GO: 0007165) and gene expression (GO: 0010467) were the highly significant enrichment of the GO biological process. Furthermore, protein binding (GO: 0005515), nucleotide binding (GO: 0000166) and ATP binding (GO: 0005524) were the highest enrichment of the GO molecular function.

10.7717/peerj.3078/table-3

###### GO annotation of dysregulated DEGs in RA.

![](peerj-05-3078-g008)

  GO Items                 GO terms                                                               Genes   FDR
  ------------------------ ---------------------------------------------------------------------- ------- ------------
  **Biological process**                                                                                  
  GO:0008380               RNA splicing                                                           19      9.89E--08
  GO:0007165               Signal transduction                                                    35      2.39E--05
  GO:0010467               Gene expression                                                        19      3.43E--05
  GO:0016477               Cell migration                                                         10      5.30E--05
  GO:0006397               mRNA processing                                                        13      5.31E--05
  GO:0000398               Nuclear mRNA splicing, via spliceosome                                 12      5.64E--05
  GO:0045944               Positive regulation of transcription from RNA polymerase II promoter   21      0.00018566
  GO:0046777               Protein autophosphorylation                                            10      0.00062775
  GO:0006355               Regulation of transcription, DNA-dependent                             37      0.00104687
  GO:0070934               CRD-mediated mRNA stabilization                                        3       0.00127416
  **Molecular Function**                                                                                  
  GO:0005515               Protein binding                                                        162     4.77E--48
  GO:0000166               Nucleotide binding                                                     66      3.56E--13
  GO:0005524               ATP binding                                                            45      3.29E--08
  GO:0003677               DNA binding                                                            47      7.84E--07
  GO:0003723               RNA binding                                                            22      8.07E--05
  GO:0003676               Nucleic acid binding                                                   25      0.000137
  GO:0003724               RNA helicase activity                                                  4       0.000148
  GO:0003713               Transcription coactivator activity                                     12      0.000202
  GO:0003700               Sequence-specific DNA binding transcription factor activity            26      0.000207
  GO:0004497               Monooxygenase activity                                                 7       0.000214

**Notes.**
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Pathway enrichment analysis
---------------------------

KEGG analysis was used to understand the signaling pathway enrichment of DEGs in RA. The threshold was FDR \< 0.05. As [Table 4](#table-4){ref-type="table"} shown, the significant enrichment of pathways focused on axon guidance (hsa04360), RNA transport (hsa03013), protein processing in endoplasmic reticulum (hsa04141) and MAPK signaling pathway (hsa04010).

Protein-protein interaction network
-----------------------------------

The PPI network between the top 10 up- and down-regulated DEGs in RA were constructed by Cytoscape based on the BioGRID database ([Fig. 2](#fig-2){ref-type="fig"}). The network consisted of 419 nodes and 480 edges. In the network, the nodes with high degree were defined as hub proteins. The hub proteins in the PPI network including RBFOX2 (degree = 90), LCK (degree = 78), SERBP1 (degree = 45), TCOF1 (degree = 36) and TARS (degree = 32), as [Fig. 2](#fig-2){ref-type="fig"} shown. A total of 402 predicted proteins interaction with top 10 up- and down-regulated were overlapped with 202 up- and 168 down-regulated DEGs, respectively. Lastly, 15 DEGs interacted with top 10 up- and down-regulated DEGs were obtained and their interactions were shown in [Table S2](#supp-2){ref-type="supplementary-material"}. RBFOX2 interacted with 6 dysregulated DEGs including DDX5, ATN1, ESR2, RPA2, RRPA3 and ATXN2; LCK interacted with WASL; SERBP1 interacted with PIAS1; TCOF1 interacted with RPA2, RPA3, TOP1 and NOP56.

![Hierarchical clustering analysis based on the expression profile of the top 200 discriminatory DEGs between synovial tissues of RA and normal controls.\
The color scale illustrated the relative expression level of mRNA across all samples; red color represented an expression level above mean, green color represented expression lower than the mean.](peerj-05-3078-g001){#fig-1}

10.7717/peerj.3078/table-4

###### KEGG enrichment of dysregulated DEGs in RA.

![](peerj-05-3078-g009)

  KEGG ID    KEGG terms                                     FDR        Genes
  ---------- ---------------------------------------------- ---------- ---------------------------------------------------------------------------
  hsa04360   Axon guidance                                  0.010565   DCC, SEMA6A, SEMA4D, PLXNA2, RGS3, NFAT5, CDK5, UNC5C
  hsa03013   RNA transport                                  0.015948   EIF5B, SAP18, GEMIN4, PABPC1, THOC2, EIF1B, EIF3E
  hsa00982   Drug metabolism - cytochrome P450              0.017355   ALDH1A3, CYP1A2, CYP3A5, MGST3, UGT2B15
  hsa00980   Metabolism of xenobiotics by cytochrome P450   0.017377   ALDH1A3, CYP1A2, CYP3A5, MGST3, UGT2B15
  hsa05200   Pathways in cancer                             0.018693   PPARD, PIAS2, DCC, E2F3, PTEN, PDGFA, CSF1R, MAPK8, PIAS1, BRCA2, CEBPA
  hsa03040   Spliceosome                                    0.020842   DHX15, HNRNPA1, DHX16, THOC2, PRPF3, HNRNPU, SRSF5
  hsa04910   Insulin signaling pathway                      0.021514   RPS6KB1, MAPK8, MKNK2, TSC1, PHKA1, PRKAG1, PPP1CB
  hsa05016   Huntington's disease                           0.021575   POLR2J, NDUFA2, UQCRC1, TGM2, BBC3, NDUFA7, GRIN1, ATP5O
  hsa05010   Alzheimer's disease                            0.023516   NDUFA2, UQCRC1, CAPN2, NDUFA7, GRIN1, ATP5O, CDK5
  hsa04141   Protein processing in endoplasmic reticulum    0.024488   SEC63, P4HB, SAR1A, CAPN2, MAPK8, AMFR, HERPUD1
  hsa03060   Protein export                                 0.02558    SRP54, SEC63, SEC11A
  hsa04010   MAPK signaling pathway                         0.026502   MAPK8IP2, PDGFA, RRAS, MAPK8, MAP3K11, MKNK2, DUSP3, STK3, CACNB2, MAP3K8
  hsa03440   Homologous recombination                       0.031046   RPA2, RPA3, BRCA2
  hsa05160   Hepatitis C                                    0.033309   PIAS2, MAPK8, PIAS1, IFNA21, IRF9, EIF3E

**Notes.**
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![The protein-protein interaction network of the top 10 up- and down-regulated DEGs in synovial tissues of RA.\
White and grey rectangle nodes represented up- and down-regulated DEGs, respectively. White ellipse nodes denoted products of genes predicted to interact with the DEGs. The solid line indicated the interaction correlation between proteins.](peerj-05-3078-g002){#fig-2}

Construction of transcription factors regulatory network
--------------------------------------------------------

In our study, TFs regulatory network under the regulation of TFs and target genes were constructed. Based on the TRANSFAC database, total of 42 proteins were identified as TFs of top 10 up- and down-regulated DEGs in RA. The identified TFs and target genes were applied to construct the TFs-target genes network by Cytoscape software. As shown in [Fig. 3](#fig-3){ref-type="fig"}, the network consisted of 61 nodes and 142 edges. The DEGs, such as RBFOX2 (degree = 16), POU6F1 (degree = 11), WIPF1 (degree = 10), PFKFB3 (degree = 9) and EIF5B (degree = 9) had the high connectivity with TFs.

![The transcription factors-target genes regulatory network of top 10 up and down-regulated DEGs in synovial tissues of RA.\
Transcription factors can regulate gene expression through binding to the promoter regions of target genes. The white and grey rectangle nodes represented up- and down-regulated DEGs, respectively. The ellipse nodes represented transcription factors. Solid lines represented regulatory correlation between transcription factors and DEGs. For instance, NSA2 was down-regulated in synovial tissues of RA and its expression level can be regulated by six transcription factors including CP2, COMP1,Nkx2-5, OCT1, Pax4 and HNF-1 based on TRANSFAC database prediction.](peerj-05-3078-g003){#fig-3}

The expression levels of DEGs were analyzed in the [GSE17755](GSE17755) datasets
--------------------------------------------------------------------------------

[GSE17755](GSE17755) covered the expression profiling of peripheral blood cells from 112 RA patients and 45 health individuals. The descriptive statistics (spread and distribution) of DEGs expression in RA patients compared to healthy individuals were depicted by using box-plot analysis, which was visually illustrated by median and inter-quartile range. As [Figs. 4F](#fig-4){ref-type="fig"}, [4G](#fig-4){ref-type="fig"} and [4K](#fig-4){ref-type="fig"} shown, the expression levels of MAT2A and NSA2 were significantly down-regulated and CD47 had the up-regulated tendency in peripheral blood cells of patients with RA, which were consistent with our integrated analysis in RA synovial tissues. However, the expression of LCK, SERBP1, WIPF1, PFKFB3, RBFOX2, ATF6B, POU6F1 and CA5A in [GSE17755](GSE17755) was incompatible with our integrated analysis in RA synovial tissues ([Figs. 4A](#fig-4){ref-type="fig"}--[4E](#fig-4){ref-type="fig"}, [4H](#fig-4){ref-type="fig"}--[4J](#fig-4){ref-type="fig"}).

![The expression levels of DEGs was analyzed in the [GSE17755](GSE17755) dataset.\
Box-plot diagram was used to describe the median and inter-quartile range of DEGs expression including LCK (A), SERBP1 (B), WIPF1 (C), PFKFB3 (D), RBFOX2 (E), CD47 (F), MAT2A (G), ATF6B (H), POU6F1 (I), CA5A(J) and NSA2(K).](peerj-05-3078-g004){#fig-4}

qRT-PCR validation of the expression levels of candidate genes in RA
--------------------------------------------------------------------

qRT-PCR was subjected to validate the expression levels of dysregulated genes in peripheral blood samples of 10 RA patients and 10 healthy individuals. Three candidate DEGs including MAT2A, NSA2 and CD47 were used to apply for qRT-PCR verification. As [Figs. 5A](#fig-5){ref-type="fig"} and [5B](#fig-5){ref-type="fig"} shown, MAT2A (*P* \< 0.01) and NSA2 (*P* \< 0.05) were obviously down-regulated in peripheral blood samples of RA patients compared with healthy individuals. However, the expression level of CD47 (*P* \> 0.05) in peripheral blood samples was not significant difference between RA patients and healthy individuals, but its expression displayed the up-regulated tendency in peripheral blood samples of RA patients.

Discussion
==========

Rheumatoid arthritis, a chronic inflammatory disease of joint, is triggered by the complex interaction between genetic susceptibility and dysregulated genes. The clinical manifestations of RA patients present pannus and the abnormal proliferative synovial tissue. Early diagnosis would improve the prognosis and the life quality of RA patients. However, the pathogenesis mechanism of RA is ambiguous and there are no feasible biomarkers for early diagnosis in clinical practice. In our study, bioinformatics analysis-based identification of key genes and pathways in RA were conducted, aiming to provide valuable ground work for further investigation of pathogenesis mechanism of RA.

![qRT-PCR validation of candidate DEGs in peripheral blood samples of RA patients and healthy individuals.\
(A) The expression level of MAT2A; (B) the expression level of NSA2; (C) the expression level of CD47. RA represented rheumatoid arthritis and CON represented healthy individuals. \* represented *P* \< 0.05 and \*\* represented *P* \< 0.01.](peerj-05-3078-g005){#fig-5}

RBFOX2 belongs to binding protein, is thought to be a key regulator of alternative exon splicing in the nervous system and other cell types ([@ref-38]). It was one of top 10 up-regulated genes in RA synovial tissues ([Table 2](#table-2){ref-type="table"}). In the TFs regulatory network, RBFOX2 had the highest connectivity with TFs, was regulated by 16 TFs. RBFOX2 is involved in various diseases and biological processes including congenital heart disease, breast cancer, epithelial-mesenchymal transition and pluripotent stem cell differentiation ([@ref-13]; [@ref-2]; [@ref-6]; [@ref-39]). The mutations of RBFOX2 are associated with congenital heart disease and neuro developmental disabilities ([@ref-13]). During the epithelial-mesenchymal transition, RBFOX2 is an essential regulator to mediate cellular invasion ([@ref-2]). To our knowledge, our study first reported the aberrant expression of RBFOX2 in RA, however, the biological function of RBFOX2 in RA needs to be further elucidated.

*CD47* encodes CD47 molecule, a membrane protein, is involved in the increase of intracellular calcium concentration and may play an essential role in membrane transport and signal transduction ([@ref-15]). CD47 was significantly down-regulated in RA ([Table 2](#table-2){ref-type="table"}). In the TFs regulatory network, CD47 was targeted by 6 TFs including v-Myb, SOX-9, HNF-1, COMP-1, E2F and Elk-1. In RA, the interaction between CD47 and thrombospondin-1 could trigger T cell infiltration and expansion in the rheumatoid synovium, and perpetuates the inflammatory process in the rheumatoid joint ([@ref-37]). CD47 might play essential roles in the progression of RA. In our study, the expression level of CD47 was increased in synovial tissues and peripheral blood cells of patients with RA ([Fig. 4F](#fig-4){ref-type="fig"}).

*MAT2A* encodes methionine adenosyltransferase 2A, is an enzyme that catalyzes the production of S-adenosylmethionine (AdoMet) from methionine and ATP, and is a key methyl donor in cellular processes ([@ref-25]). In our study, MAT2A was the most significantly down-regulated DEG in synovial tissues of RA ([Table 2](#table-2){ref-type="table"}). The previous studies display that MAT2A is associated with uncontrolled cell proliferation in cancer. The protein expression level of MAT2A is decreased in renal cell carcinoma compared to normal tissues ([@ref-40]), while MAT2A is over-expressed in various gastrointestinal cancers, such as gastric cancer, colon cancer and liver cancer ([@ref-46]; [@ref-35]). miR-21-3p targets down-regulation of MAT2A and inhibits cell growth in hepatoma ([@ref-20]). Based on aforementioned information, down-regulated MAT2A in synovial tissues of RA might implicate in cell proliferation, invasiveness of fibroblast-like synoviocytes, which results in erosion of bone and cartilage in RA. The expression of MAT2A in synovial tissues and FLS needs to be validated through quantitative real-time polymerase chain reaction in a larger sample size of patients with RA and healthy individuals, in addition, the biological roles of MAT2A in FLS needs to be further investigated through *in vivo* and *in vitro* experiment. MAT2A had the lower expression in both of peripheral blood cells and synovial tissues of RA patients compared to healthy individuals ([Fig. 4G](#fig-4){ref-type="fig"}).

NSA2 encodes NSA2 (Nop seven-associated 2), ribosome biogenesis homolog, locates in the nucleolus of the cell, and is involved in cell cycle regulation and proliferation ([@ref-45]). It had the lower expression level in synovial tissues and peripheral blood cells of RA patients compared to healthy individuals ([Table 2](#table-2){ref-type="table"}, [Fig. 4K](#fig-4){ref-type="fig"}). Over-expression of the NSA2 protein promotes cell growth and regulates the G1/S transition in the cell cycle in different cell lines including HeLa (human cervical carcinoma), HEK293T (human embryonic kidney) and A549 (human epithelial lung adenocarcinoma) ([@ref-45]; [@ref-19]). The association between dysregulated NSA2 and pathogenesis of RA has not been reported. The functions of NSA2 in initiation and progression of RA need to be elucidated in the future study.

Dysregulated DEGs were identified in synovial tissues of patients with RA, and the mRNA expression level of representative DEGs was preliminarily detected in peripheral blood cells of patients with RA based on [GSE17755](GSE17755) dataset. As [Fig. 4](#fig-4){ref-type="fig"} shown, LCK, SERBP1, WIPF1, PFKFB3 and RBFOX2 were down-regulated in peripheral blood cells of RA, but those genes were up-regulated in synovial tissues of RA; POU6F1 and CA5A were down-regulated in peripheral blood cells of RA, but they were up-regulated in synovial tissues of RA. The contradictory expression status of DEGs in synovial tissues and peripheral blood cells might attribute to different characteristics of expression profiling between synovial tissues and peripheral blood cells in patients with RA. In our bioinformatics analyses, the expression levels of MAT2 and NSA2 were obviously down-regulated both in synovial tissues and peripheral blood samples of RA patients; and CD47 expression was up-regulated both in synovial tissues and with the up-regulated tendency in peripheral blood samples of RA patients. The expression status of MAT2, NSA2 and CD47 in peripheral blood samples of RA patients were validate through qRT-PCR. The qRT-PCR results indicated MAT2A and NSA2 were significantly down-regulated in peripheral blood samples of RA patients and CD47 had the up-regulated tendency in peripheral blood samples of RA patients compared with healthy individuals ([Fig. 5](#fig-5){ref-type="fig"}). In general, qRT-PCR results of MAT2A, NSA2 and CD47 were compatible with our bioinformatics analyses. The associations between a majority of identitied TFs in the TF-gene regulatory network and RA remain unknown. The roles of a number of identified TFs in other autoimmue disorders are explored. c-Ets-1 belongs to the ETS family of transcript factors and regulates the expression of various immune-related genes. In our work, it was predicted to bind with the promoter of SAR1A, SERBP and TARS. Over-expression of c-Ets-1 in synovial membrane regulates inflammatory angiogenesis in RA through being activated by interleukin-1 and tumor necrosis factor alpha ([@ref-42]; [@ref-28]). A eQTL analysis indicates that the allele of [rs6590330](http://www.ncbi.nlm.nih.gov/snp/?term=rs6590330) in ETS1 is associated with decreased ETS1 expression and increases the risk of systemic lupus erythematosus by enhancing the binding of pSTAT1 ([@ref-21]). The regulatory significance of identified TFs in development and progression of RA needs to be profoundly investigated in our future work.

The dysregulated genes in RA were significantly enriched in KEGG pathways including axon guidance, RNA transport and MAPK signaling pathway. Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, slits, and semaphorins. Catalano reports that semaphoring-3A (SEMA3A), a number of semaphorin family, attenuates inflammation and progression of collagen-induced arthritis ([@ref-5]). SEMA3A is decreased in the immune system of experimental autoimmune encephalomyelitis murine model of multiple sclerosis, which is one of autoimmunity diseases ([@ref-12]). In our study, down-regulated SEMA6A and up-regulated SEMA4D were significantly enriched in axon guidance pathway. THOC2 (interacted with NR5A1 in PPI network) and EIF58 (one of the top 10 up-regulated DEGs in RA) were significantly enriched in RNA transport pathways. The mitogen-activated protein kinase (MAPK) cascade is involved in various cellular functions, including cell proliferation, differentiation and migration. A series of articles depict that MAPK signaling pathway associates with RA ([@ref-26]; [@ref-41]; [@ref-30]). Increased expression of phosphorylation ezrin may contribute to migration and invasion of fibroblast-like synoviocytes in RA, which are mediated by rho kinase and the p38 MAPK pathway phosphorylation ([@ref-44]). BRAF splice variants activate MAPK through CRAF, increase expression of MT1-MMP, and enhance fibroblast invasion of collagen in RA. Based on the abovementioned information, axon guidance, RNA transport and MAPK signaling pathway might contribute to the progression of RA.

In our study, RBFOX2 and those dysregulated DEGs interacted with it including DDX5, ATN1, ESR2, RPA2, RPA3 and ATXN2 were significantly enriched in six significant enrichment of biological process and molecular function, such as RNA splicing, signaling transduction, gene expression, protein binding , nucleotide binding and ATP binding ([Table S1](#supp-1){ref-type="supplementary-material"}). NPM1 (interacted with NAS2) was significantly enriched in signal transduction and protein binding ([Table S1](#supp-1){ref-type="supplementary-material"}). Our finding indicated that the protein-protein interactions between dysregulated DEGs might play essential roles in progression and development of RA through those biological processes and molecular functions.

There are limitations in our study. Firstly, further biological function studies should be performed to investigate the roles of these DEGs and pathways in the progression of RA. Secondly, whether those dysregulated genes in RA have the diagnostic value in RA diagnosis needs to be validated through large cohorts of RA patients and healthy individuals.

Conclusions
===========

In conclusion, we identified 378 DEGs in synovial tissues of RA patients compared to healthy individuals. The top 10 up- and down-regulated genes were selected to establish the PPI network and TF-target genes network. The expression levels of candidate DEGs was preliminarily detected in peripheral blood cells of RA according to [GSE17755](GSE17755) dataset. Our study indicated that dysregulated genes in RA might contribute to the progression of RA by regulating biological process, molecular function and signaling pathways based on complex gene regulatory network interaction, such as PPI network and TF-genes regulatory network. Our findings may pave the road for exploring the underlying mechanisms of RA and identifying the potential biomarkers for RA diagnosis.
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###### The top 10 up-/down-regulated DEGs and those DEGs interacted with top 10 up-/down-regulated DEGs enriched in GO terms

DEGs, differentially expressed genes; FDR, false discovery rate; NA, not available.

###### 

Click here for additional data file.
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###### The DEGs interacted with the top 10 up- and down-regulated DEGs in RA

NA: not applicable; DEGs: differentially expressed genes; RA: rheumatoid arthritis. The predicted proteins of TRD, POU6F1 and CA5A were not available in the BioGRID database and were not shown in Table S2.

###### 

Click here for additional data file.
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